Lingual Raynaud’s Phenomenon: A Case Series and Literature Review
Abstract
1. Introduction
2. Patient and Method
2.1. Patients
2.2. Literature Review
2.3. Statistical Analysis
3. Results
3.1. Present Report
3.2. Review of Literature Associated with the Case Series
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Generini, S.; Kahaleh, B.; Matucci-Cerinic, M.; Pignone, A.; Lombardi, A.; Ohtsuka, T. Raynaud’s phenomenon and systemic sclerosis. Ann. Ital. Med. Int. 1996, 11, 125–131. [Google Scholar] [PubMed]
- Flavahan, N.A.; Flavahan, S.; Mitra, S.; Chotani, M.A. The vasculopathy of Raynaud’s phenomenon and scleroderma. Rheum. Dis. Clin. N. Am. 2003, 29, 275–291. [Google Scholar] [CrossRef] [PubMed]
- Aqtash, O.; Ajmeri, A.N.; Thornhill, B.A.; Anderson, E.; Carroll, R.; Elhamdani, A.; Tackett, E. A Unique Case of Tenofovir-Induced DRESS Syndrome Associated with Raynaud’s of the Tongue. Int. J. Gen. Med. 2019, 12, 381–385. [Google Scholar] [CrossRef] [PubMed]
- Nakashima, Y.; Fujihira, T.; Fukuchi, Y.; Ishii, N.; Imaizumi, T.; Miyahara, K.; Takasugi, M.; Kuroiwa, A. Autopsy findings of the coronary arteries of variant angina with Raynaud’s phenomenon of the tongue. Jpn. Heart J. 1986, 27, 107–116. [Google Scholar] [CrossRef][Green Version]
- Boukovalas, S.; Mays, A.C.; Selber, J.C. Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. Ann. Plast. Surg. 2019, 82, 53–54. [Google Scholar] [CrossRef]
- Katada, Y.; Tanaka, T. Images in clinical medicine. Lingual Raynaud’s phenomenon. N. Engl. J. Med. 2012, 366, e12. [Google Scholar] [CrossRef]
- Kuhl, V.; Urban, P.P.; Mayet, W.J.; Hopf, H.C. Isolated trochlear nerve palsy and repetitive Raynaud’s phenomenon of the tongue in primary Sjögren’s syndrome. J. Neurol. 1999, 246, 974–975. [Google Scholar] [CrossRef]
- Ghiam, A.F.; Cho, J. Lingual Raynaud phenomenon. CMAJ 2015, 187, 1160. [Google Scholar] [CrossRef]
- Murphy, N.J.; Kabbani, L.S.; Shepard, A.D.; Siddiqui, F. Lingual Raynaud’s Phenomenon after Surgical and Radiotherapeutic Intervention for Oral Squamous Cell Carcinoma. Case Rep. Vasc. Med. 2022, 2022, 1567581. [Google Scholar] [CrossRef]
- Biddle, K.; Kaul, A. Lingual Raynaud’s phenomenon: A rare presentation. BMJ Case Rep. 2022, 15, e251988. [Google Scholar] [CrossRef]
- Nielsen, H.V.; Kristensen, J.K.; Klemp, P.; Staberg, B.; Thomsen, K. Paroxysmal dysarthria and Raynaud’s phenomenon in the tongue. Acta Med. Scand. 1984, 216, 431–432. [Google Scholar] [CrossRef]
- Basharat, R.; Riordan, J.; Samara, G. Primary Raynaud’s Phenomenon of the Tongue. Cureus 2024, 16, e67417. [Google Scholar] [CrossRef] [PubMed]
- Casey, E.B.; Lawton, N.F. Progressive systemic sclerosis presenting with Raynaud’s phenomenon in the tongue and sensory trigeminal neuropathy. Rheumatol. Phys. Med. 1971, 11, 131–133. [Google Scholar] [CrossRef] [PubMed]
- Giunta, J.L. Raynaud disease with oral manifestations. Arch. Dermatol. 1975, 111, 78–80. [Google Scholar] [CrossRef] [PubMed]
- Chatterjee, S. Raynaud phenomenon causing lingual pallor and dysarthria. CMAJ 2016, 188, E396. [Google Scholar] [CrossRef]
- Rosato, E.; Salsano, F. Raynaud phenomenon of the tongue in a patient with scleroderma. J. Clin. Rheumatol. 2010, 16, 201. [Google Scholar] [CrossRef]
- Hunter, J.A.; Levy, D.M.; Berard, R.A. Raynaud Phenomenon with Lingual Involvement in a 6-year-old Female. J. Rheumatol. 2021, 48, 465–466. [Google Scholar] [CrossRef]
- Perry, M.E.; Surtee, S.; Nawaz, Z. Raynaud’s of the Tongue. Eur. J. Case Rep. Intern. Med. 2017, 4, 000689. [Google Scholar] [CrossRef]
- Mittal, A.; Mittal, B.B. Raynaud’s of the tongue following chemoradiation for squamous cell carcinoma of the oropharynx. Mol. Clin. Oncol. 2017, 6, 187–188. [Google Scholar] [CrossRef]
- Bridges, M.J.; Kelly, C.A. Raynaud’s phenomenon affecting the tongue of a patient with scleroderma. Ann. Rheum. Dis. 2002, 61, 472. [Google Scholar] [CrossRef]
- Westbury, C.B.; Harrington, K.J.; Rhys-Evans, P.; Archer, D.J.; Searle, A.E.; Henk, J.M.; Black, C.M.; Nutting, C.M. Raynaud’s phenomenon after radical radiotherapy for tumours of the head and neck. Postgrad. Med. J. 2003, 79, 176–177. [Google Scholar] [CrossRef][Green Version]
- Cohen, J.C.; Palomba, M.L.; Morris, L.G.T. Raynaud’s phenomenon of the tongue. J. Rheumatol. 2013, 40, 336. [Google Scholar] [CrossRef]
- Grémain, V.; Richard, L.; Langlois, V.; Marie, I. Raynaud’s phenomenon of the tongue. Jt. Bone Spine 2017, 84, 231. [Google Scholar] [CrossRef]
- Lioger, B.; Diot, E. Raynaud’s phenomenon of the tongue: Uncommon presentation of a classical sign. QJM Int. J. Med. 2013, 106, 583–584. [Google Scholar] [CrossRef][Green Version]
- Bang, F.d.C.; Wantzin, G.L.; Christensen, J.D. Raynaud’s phenomenon with oral manifestation in systemic lupus erythematosus. Dermatology 1985, 170, 263–264. [Google Scholar] [CrossRef]
- Zeni, S.; Ingegnoli, F. Raynaud’s phenomenon. Reumatismo 2004, 56, 77–81. [Google Scholar] [CrossRef]


| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Age at diagnosis of SS (y-o) | 23 | 47 | 44 | 22 | NA |
| Antinuclear antibody specificity | anti-Scl-70 | non-specific | anti-centromere | anti-centromere | anti-Scl-70 |
| Presence of fingers RP | Yes | Yes | Yes | Yes | Yes |
| Age at diagnosis of RP (y-o) | 23 | 27 | 24 | 20 | NA |
| Other clinical manifestations of SS | Digital ulcer Interstitial lung disease | Digital ulcer | None | None | Digital ulcer Interstitial lung disease PHTN |
| Maintenance therapy for the connective tissue disease | Prednisone | None | None | None | Prednisone MMF |
| Age at diagnosis of LRP (y-o) | 32 | 32 | 45 | 20 | 45 |
| Sex | Female | Female | Female | Female | Male |
| BMI Kg/m2 | 22.8 | 23.7 | 36.7 | NA | NA |
| Weight loss contemporaneous with the onset of LRP | None | None | None | None | None |
| Active smoking at diagnosis of LRP | None | None | Yes | None | None |
| Characteristics of LRP | |||||
| Presence of a syncopal phase | Yes | Yes | Yes | Yes | Yes |
| Presence of a cyanotic phase | Yes | Yes | Yes | Yes | Yes |
| Presence of a lingual ulceration | None | None | None | None | None |
| Maximum duration of attacks (in minutes) | NA | 10 | 5 | 3 | 1 |
| Presence of dysarthria | Yes | Yes | Yes | None | None |
| Triggered by general cold exposure | Yes | Yes | Yes | Yes | Yes |
| Triggered by intake of cold food or drink | None | None | None | None | None |
| Spontaneous events | Yes | None | None | Yes | Yes |
| Treatments | |||||
| Vasodilator treatment | Yes | Yes | Yes | Yes | Yes |
| Vasodilator molecule used | Nifedipine | Nifedipine | Nifedipine | Ilomedine | Amlodipine |
| Effect of vasodilator treatment on LRP (reducing number and duration of attacks) | Benefic | Benefic | Benefic | Benefic | No benefit |
| Systemic Sclerosis n = 14 | ENT Cancer with Radiotherapy n = 6 | Idiopathic n = 10 | |
|---|---|---|---|
| Presence of fingers RP | 14 (100%) | 3 (50%) | 4 (40%) |
| Age at diagnosis of RP (y-o) | 22.8; 23.5 | 35.7; 37 | 24.3; 22 |
| Age at diagnosis of LRP (y-o) | 35.9; 32 | 52.7; 50.5 | 40.8; 48 |
| Male gender | 1 (7.1%) | 1 (16.7%) | 4 (40%) |
| BMI Kg/m2 | 27.7; 23.7 | - | 20.1; 20.1 |
| Weight loss contemporaneous with the onset of LRP | 0 (0%) | 1 (16.7%) | 1 (10%) |
| Active smoking at diagnosis of LRP | 1 (7.1%) | 0 (0%) | 6 (60%) |
| Former smoking | 2 (14.3%) | 3 (50%) | 5 (50%) |
| Cumulative consumption (pack-years) | 23.0; 25 | 15.0; 15 | 37.2; 25 |
| Presence of a syncopal phase | 7 (87.5%) | 6 (100%) | 9 (90%) |
| Presence of a cyanotic phase | 14 (100%) | 3 (50%) | 3 (30%) |
| Presence of a lingual ulceration | 0 (0%) | 0 (0%) | 0 (0%) |
| Maximum duration of attacks (in minutes) | 9; 10 | 6; 4 | 6; 3 |
| Presence of dysarthria | 9 (64.3%) | 2 (33.3%) | 4 (40%) |
| Triggered by general cold exposure | 9 (64.3%) | 6 (100%) | 8 (80%) |
| Triggered by intake of cold food or drink | 0 (0%) | 1 (16.7%) | 0 (0%) |
| Spontaneous events | 9 (64.3%) | 3 (50%) | 4 (40%) |
| Initiated vasodilator treatment | 8 (57.1%) | 1 (16.7%) | 2 (20%) |
| Positive effect of vasodilator treatment on LRP | 7/8 (87.5%) | 1/1 (100%) | 0/0 (0%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Morard, M.; Brebion, N.; Lambert, M.; Diot, E.; Lioger, B.; Kubina, J.-M.; Agard, C.; Espitia, O. Lingual Raynaud’s Phenomenon: A Case Series and Literature Review. J. Clin. Med. 2026, 15, 1738. https://doi.org/10.3390/jcm15051738
Morard M, Brebion N, Lambert M, Diot E, Lioger B, Kubina J-M, Agard C, Espitia O. Lingual Raynaud’s Phenomenon: A Case Series and Literature Review. Journal of Clinical Medicine. 2026; 15(5):1738. https://doi.org/10.3390/jcm15051738
Chicago/Turabian StyleMorard, Marie, Nicolas Brebion, Marc Lambert, Elisabeth Diot, Bertrand Lioger, Jean-Manuel Kubina, Christian Agard, and Olivier Espitia. 2026. "Lingual Raynaud’s Phenomenon: A Case Series and Literature Review" Journal of Clinical Medicine 15, no. 5: 1738. https://doi.org/10.3390/jcm15051738
APA StyleMorard, M., Brebion, N., Lambert, M., Diot, E., Lioger, B., Kubina, J.-M., Agard, C., & Espitia, O. (2026). Lingual Raynaud’s Phenomenon: A Case Series and Literature Review. Journal of Clinical Medicine, 15(5), 1738. https://doi.org/10.3390/jcm15051738

